22353-53-3 Usage
Uses
Used in Pharmaceutical Industry:
3-Chloro-2-methoxy-5-nitropyridine is utilized as an intermediate in the synthesis of pharmaceuticals. Its unique chemical properties allow it to be a key component in the development of various medications, contributing to the advancement of healthcare solutions.
Used in Agrochemical Industry:
In the agrochemical sector, 3-chloro-2-methoxy-5-nitropyridine serves as an intermediate in the production of agrochemicals. Its role in this industry is crucial for the development of effective products that protect crops and enhance agricultural productivity.
Used in Dye and Pigment Production:
3-Chloro-2-methoxy-5-nitropyridine is also employed in the manufacturing of dyes and pigments. Its chemical structure lends itself to the creation of a wide range of colorants used across various industries, including textiles, plastics, and printing inks.
Check Digit Verification of cas no
The CAS Registry Mumber 22353-53-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,2,3,5 and 3 respectively; the second part has 2 digits, 5 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 22353-53:
(7*2)+(6*2)+(5*3)+(4*5)+(3*3)+(2*5)+(1*3)=83
83 % 10 = 3
So 22353-53-3 is a valid CAS Registry Number.
22353-53-3Relevant academic research and scientific papers
NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF
-
Paragraph 1105; 1106, (2018/09/08)
An object of the present invention is to provide to a compound and a pharmaceutical composition, which have excellent Syk-inhibitory activity. Th e present invention provides a nicotinamide derivative represented by the follo wing formula (I) (wherein R 1 represents a halogen atom; R 2 represents a C 1-12 alkyl group, a C 2-12 alkenyl group, a C 2-12 alkynyl group, a C 3-8 cycloalkyl g roup, an aryl group, an ar-C 1-6 alkyl group or a heterocyclic group, each opti onally having at least one substituent; R 3 represents an aryl group or a hetero cyclic group each optionally having at least one substituent; and R 4 and R 5 e ach independently represent a hydrogen atom; and R 2 and R 4 may form a cyc lic amino group optionally having at least one substituent together with the ni trogen atom to which they bind) or a salt thereof, and a pharmaceutical comp osition for use in the treatment of a Syk-related disease which comprises the nicotinamide derivative or a salt thereof.
